english.prescrire.org > Spotlight > Archives : 2026 > Momelotinib (Omjjara°) in myelofibrosis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Momelotinib (Omjjara°) in myelofibrosis

 Marketing Authorisations  The immunosuppressant momelotinib has been authorised in the European Union for use in patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Does momelotinib extend survival in these patients? Does it alleviate symptoms more than existing drugs, particularly ruxolitinib? And what are its adverse effects? 
Full article available for download by subscribers

 ©Prescrire 1 January 2026

Source: "Momelotinib (Omjjara°) in myelofibrosis" Prescrire Int 2026; 35 (277): 10-11. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Fedratinib (Inrebic°)
in myelofibrosis"
Prescrire Int 2023;
32 (247): 97.
Subscribers only